​

Autolus Therapeutics announced that on 11/8/24, the US Food and Drug Administration (FDA) approved AUCATZYL® (obecabtagene autoleucel), a chimeric antigen receptor (CAR) T-cell therapy for the

treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL).

 

The whole sale acquisition price is 525K plus administration charges. AUCATZYL® is the first CAR-T therapy approved by the US Food and Drug Administration (FDA) with no requirement for a Risk Evaluation Mitigation Strategy (REMS) program.

​